ClinicalTrials.gg
CompletedNCT07423286Updated Feb 20, 2026

A Study to Understand What the Body Does to the Study Medicine Called PF-07248144 When Taken by Healthy Adults

A Phase 1 interventional study of Oral [14C] PF-07248144 and Oral unlabeled PF-07248144 in Healthy Adult Participants, sponsored by Pfizer. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

For this study, the study medicine has been specially prepared to contain radiolabeled carbon [14C]. [14C] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study medicine does not change how the medicine works but helps to see how the medicine appears in the blood, urine, and stool after it is given. This type of study is called a radiolabeled study.

The purpose of this radiolabeled study is to learn how a certain amount of [14C] PF-07248144 is taken up into the bloodstream and removed from the body.

The study is seeking participants who are:

  • females who cannot have children, or males
  • 18 years of age or older
  • confirmed to be healthy based on medical and physical tests.
  • weigh more than 50 kilograms (kg) and have a body mass index of 18 to 32 kg per meter squared.

The study consists of two parts. In part one, all participants will receive one full dose of [14C]PF-07248144 by mouth. Part two will begin at least 28 days after the dose in part one. In part two, participants will receive one full dose of PF-07248144 by mouth and one small dose of [14C] PF-07248144 by intravenous (IV) infusion. IV infusion will be directly injected into the veins.

To understand how the medicine is processed in the body, samples of blood, urine, feces, and vomit (if any) will be collected after each dose is given. This will help understand:

  • How much PF-07248144 is taken up into the bloodstream when taken by mouth compared to the dose given by IV
  • How the body removes it from the blood steam.

Participants will take part in the study for about 15 weeks, including evaluation at the start and follow-up period.

02

Conditions studied

  • Healthy Adult Participants
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female of nonchildbearing potential or male ≥18 years of age, inclusive, at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and 12-lead ECGs.
  • of 18-32 kg/m2; and a total body weight >50 kg (110 lb).

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing.
  • Previous administration of an product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.
  • Total 14C radioactivity measured in plasma should not exceed 2.5 × standard biological carbon ratio.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive one dose of \[14C\] PF-07248144 by mouth in Period 1. After a washout, participants will receive one dose of PF-07248144 by mouth and one intravenous (IV) infusion of \[14C\] PF-07248144 in Period 2

    Drug: Oral [14C] PF-07248144 · Drug: Oral unlabeled PF-07248144 · Drug: IV [14C] PF-07248144

Interventions

  • A single oral dose of \[14C\] PF-07248144 will be administered as an extemporaneous suspension in Period 1

  • DrugOral unlabeled PF-07248144

    A single oral dose of unlabeled PF-07248144 will be administered as tablets in Period 2

  • A single IV infusion of \[14C\] PF-07248144 will be administered at the approximate Tmax after administration of the unlabeled oral dose of PF-07248144 in Period 2

06

What researchers measure

Primary outcomes

  1. Total recovery of radioactivity in urine, feces and vomitus (if any) expressed as a percent of total radioactive dose administered.

    To characterize the extent of excretion of total radioactivity in urine, feces, and vomitus (if any) following administration of a single oral dose of \[14C\]PF-07248144.

    Time frame: Period 1 pre-dose to maximum Days 22

  2. Metabolic profiling/identification and determination of relative abundance of [14C]PF-07248144 and the metabolites of [14C]PF-07248144 in plasma, urine, and feces.

    To characterize the metabolic profile and identify circulating and excreted metabolites following administration of a single oral dose of \[14C\]PF-07248144.

    Time frame: Period 1 pre-dose to maximum Days 22

Secondary outcomes

  1. The ratio of dose-normalized plasma AUCinf (if data permit, otherwise AUClast) of oral unlabeled PF-07248144 and IV microtracer of [14C]PF-07248144 in Period 2 only.

    To determine the absolute oral bioavailability (F) of PF-07248144 following administration of a single oral dose of PF-07248144 compared to a single IV microtracer of \[14C\]PF-07248144.

    Time frame: Period 2 pre-dose to maximum Days 10

  2. The ratio of total urinary radioactivity following oral administration of [14C]PF-07248144 in Period 1 and IV microtracer, microdose administration of [14C]PF-07248144 in Period 2.

    To determine the fraction of the dose absorbed (Fa) following administration of a single oral dose of \[14C\]PF-07248144.

    Time frame: Period 1 pre-dose to maximum Days 22; Period 2 pre-dose to maximum Days 10

  3. Number of Participants With Treatment Emergent Adverse Events

    Time frame: Baseline and through 28 to 35 days post last study intervention dose

  4. Number of Participants with Treatment Emergent Clinically Significant Laboratory Abnormalities

    Time frame: From Baseline up to 28 to 35 days post last study intervention dose

  5. Number of Participants With Treatment Emergent Clinically Significant Abnormal Vital Signs

    Time frame: From Baseline up to 28 to 35 days post last study intervention dose

  6. Number of Participants With Treatment Emergent Clinically Significant Physical Examination Abnormalities

    Time frame: From Baseline up to 28 to 35 days post last study intervention dose

  7. Number of Participants With Treatment Emergent Clinically Significant Abnormal ECG Measurements

    Time frame: From Baseline up to 28 to 35 days post last study intervention dose

07

Study locations

2 sites
  • Fortrea Clinical Research Unit - Madison
    Madison, Wisconsin 53704, United States
  • Fortrea Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Dec 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2025
First posted
Feb 20, 2026
StartActual
Oct 13, 2025
Primary completionActual
Dec 28, 2025
CompletionActual
Jan 16, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07423286
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Oct 13, 2025
Primary completion
Dec 28, 2025
Completion
Jan 16, 2026
Last update
Feb 20, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prifetrastat

Start the discussion